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Abstract 19 
 20 
Protein O-GlcNAcylation is a reversible post-translational modification of serines/threonines on 21 
nucleocytoplasmic proteins. It is cycled by the enzymes O-GlcNAc transferase (OGT) and O-GlcNAc hydrolase 22 
(O-GlcNAcase or OGA). Genetic approaches in model organisms have revealed that protein O-GlcNAcylation is 23 
essential for early embryogenesis. Drosophila melanogaster OGT/supersex combs (sxc) is a polycomb gene, 24 
null mutants of which display homeotic transformations and die at the pharate adult stage. However, the identities 25 
of the O-GlcNAcylated proteins involved, and the underlying mechanisms linking these phenotypes to embryonic 26 
development, are poorly understood. Identification of O-GlcNAcylated proteins from biological samples is 27 
hampered by the low stoichiometry of this modification and limited enrichment tools. Using a catalytically inactive 28 
bacterial O-GlcNAcase mutant as a substrate trap, we have enriched the O-GlcNAc proteome of the developing 29 
Drosophila embryo, identifying, amongst others, known regulators of Hox genes as candidate conveyors of OGT 30 
function during embryonic development. 31 
  32 
 3 
Introduction  33 
 34 
O-GlcNAcylation, the addition of a single O-linked -N-acetylglucosamine (O-GlcNAc) to serine or threonine 35 
residues on target proteins, is a post-translational modification of nucleocytoplasmic proteins regulated by two 36 
enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA)1. The donor substrate for protein O-37 
GlcNAcylation is UDP-GlcNAc, produced from the glycolytic metabolite fructose-6-phosphate through the 38 
hexosamine biosynthetic pathway. Protein O-GlcNAcylation is a dynamic and reversible modification and is 39 
responsive to alterations in nutrient status and cellular stimuli1 and has been implicated in a broad range of 40 
cellular process including gene expression, protein trafficking and degradation, stress response1 and 41 
autophagy2. Alterations in tissue specific protein O-GlcNAcylation profiles have been linked to a number of 42 
human pathologies including diabetes, cancer, cardiovascular disease and neurodegenerative disorders1. In 43 
addition, using genetic approaches, it has been demonstrated that OGT, and by extension, protein O-44 
GlcNAcylation, has a critical role in embryonic development in animals3-6, although the mechanisms 45 
underpinning this remain largely unclear. 46 
 47 
An attractive model organism to begin to dissect the links between protein O-GlcNAcylation and metazoan 48 
development is the fruit fly Drosophila melanogaster. Flies that lack zygotic expression of OGT/sxc, but retain 49 
maternally contributed OGT protein and transcripts, die at the late pupal pharate adult stage with distinct 50 
homeotic transformations3. Flies lacking both zygotic and maternal OGT/sxc arrest development at the end of 51 
embryogenesis and show homeotic transformations in the embryonic cuticle3. Studies employing ChIP 52 
experiments have shown that O-GlcNAc is highly enriched at polycomb responsive elements (PREs) in Hox and 53 
other gene clusters in Drosophila7,8. The transcription factor Polyhomeotic (Ph) is a polycomb group protein 54 
known to be O-GlcNAcylated7. It has been shown that O-GlcNAcylation of Ph prevents its aggregation, and is 55 
required for the formation of functional, ordered assemblies of the protein9. OGT/sxc null mutants recapitulate 56 
some of the developmental phenotypes of Ph null mutants10. Other studies in flies have described the association 57 
of O-GlcNAc with cellular processes like glucose-insulin homeostasis11, circadian rhythm12-14, temperature stress 58 
during development15, FGF signaling16 and autophagy17. It is therefore clear that protein O-GlcNAcylation is 59 
involved in several processes in the fly in addition to Ph-dependent Hox gene repression. Our discovery that 60 
 4 
protein O-GlcNAcylation is dynamic during Drosophila embryogenesis18 led us to pursue the proteomics-based 61 
identification of the modified proteins to aid the understanding of the mechanisms responsible for the OGT/sxc 62 
null phenotypes. While many proteomics studies have focused on the identification of O-GlcNAcylated proteins 63 
in mammalian cells and tissues, there is only a single study reporting O-GlcNAcylated proteins from Drosophila 64 
S2 cells with no site assignments19.  65 
 66 
Identification of native O-GlcNAcylated proteins by mass spectrometry is hampered by the fact that the O-GlcNAc 67 
moiety is labile and lost during standard collision induced dissociation (CID) peptide backbone fragmentation20. 68 
Additionally, given the sub-stoichiometric nature of O-GlcNAc, enrichment of modified proteins is required before 69 
they can be identified using mass spectrometry. Derivatization of modified substrates by BEMAD (β-elimination 70 
followed by Michael addition of DTT) and chemoenzymatic/metabolic labeling approaches have been used for 71 
the enrichment/site mapping of O-GlcNAcylated proteins (reviewed by 20). With the advent of electron transfer 72 
dissociation (ETD) fragmentation, in which O-GlcNAc is not labile20, strategies for the capture of native O-73 
GlcNAcylated proteins/peptides, such as lectin weak affinity chromatography using wheat germ agglutinin 74 
(WGA)21,22 or immunoprecipitation with the anti-O-GlcNAc antibody CTD110.623, have been employed for site 75 
mapping O-GlcNAcylated substrates. There are however, a number of limitations associated with these 76 
enrichment methods. In addition to O-GlcNAc, O-phosphate groups and O-glycans are also susceptible to 77 
BEMAD and rigorous optimization of reaction conditions and the use of appropriate controls such as 78 
phosphatase treatment are required to eliminate false positive identifications24. This is also true of 79 
chemoenzymatic and metabolic labeling methods, which can lead to the derivatization and enrichment of off-80 
target glycans and other chemical groups. The drawback of using WGA affinity chromatography is its millimolar 81 
affinity for GlcNAc20-22. Although possessing much improved affinity for O-GlcNAc, the anti-O-GlcNAc antibody 82 
CTD 110.6, like WGA, has been shown to recognize terminal GlcNAc residues in other glycans25,26, making it 83 
somewhat non-specific as a bait. Additionally, given that it is raised against a specific immunogen from the C-84 
terminal domain of RNA pol II27, it is possible that regardless of its specificity, CTD 110.6 does not recognize all 85 
O-GlcNAc sites. There is thus a need for novel strategies for the native enrichment of O-GlcNAcylated 86 
proteins/peptides.  87 
 88 
 5 
We previously observed that a bacterial orthologue of the eukaryotic OGAs, Clostridium perfringens NagJ 89 
(CpOGA), shares 51% sequence similarity with human OGA (hOGA) and possesses remarkable catalytic activity 90 
on human O-GlcNAcylated proteins28. We recently demonstrated that an inactive mutant of this enzyme 91 
(CpOGAD298N), which retains the ability to bind to O-GlcNAcylated peptides (Fig. 1a) with affinities down to the 92 
nM range, could be used for the detection of O-GlcNAc proteins18. Here, we demonstrate that CpOGAD298N is a 93 
powerful new tool for the enrichment of O-GlcNAcylated proteins from Drosophila embryos, and use mass 94 
spectrometry to identify the first O-GlcNAc proteome associated with embryonic development. We reveal a range 95 
of previously unknown O-GlcNAc proteins with established links to homeotic and non-homeotic phenotypes as 96 
candidate conveyors of the Drosophila OGT/sxc catalytic null phenotype. 97 
  98 
 6 
Results 99 
 100 
A tool for the enrichment of O-GlcNAcylated proteins 101 
Our earlier work on the elucidation of the catalytic mechanism of OGA, using the bacterial enzyme CpOGA as a 102 
model, revealed a number of conserved amino acids in the active site involved in catalysis28,29. In particular, 103 
Asp298 (equivalent to Asp175 in hOGA) was identified as the catalytic acid that protonates the glycosidic bond, 104 
and Asp401 (equivalent to Asp285 in hOGA) was identified as being involved in hydrogen bonding required for 105 
the anchoring of the GlcNAc moiety in the active site through its O4 and O6 hydroxyl groups (Fig. 1a). The 106 
D298N mutant of CpOGA was catalytically impaired (8100-fold decrease in kcat compared to wild type enzyme) 107 
with negligible effect on the substrate KM, while the D401A mutant demonstrated loss of binding to the model 108 
substrate 4-methylumbelliferyl-GlcNAc (4MU-GlcNAc) (5-fold increase in KM, 2400-fold decrease in kcat)28. 109 
Having previously shown that CpOGAD298N (but not the binding-deficient CpOGAD401A or the double mutant 110 
CpOGAD298N,D401A) can be used as a probe for the specific detection of O-GlcNAcylated proteins in both human 111 
and Drosophila cell/tissue lysates18, we wanted to evaluate the feasibility of using it as a substrate trap to pull 112 
down O-GlcNAcylated proteins.  113 
 114 
To this end, we first carried out a proof of principle experiment. Halo-tagged CpOGAD298N, or the double mutant 115 
CpOGAD298N,D401A as a negative control, were covalently coupled to HaloLinkTM (Promega) beads and incubated 116 
with unmodified or in vitro O-GlcNAcylated recombinant TAB1 (transforming growth factor beta-activated kinase 117 
1 binding protein 1) (Fig. 1b and Supplementary Results, Supplementary Fig. 1), a protein whose O-118 
GlcNAcylation has previously been demonstrated to modulate innate immune signaling downstream of the IL-1 119 
receptor30. Elution of enriched TAB1 from the mutant CpOGA beads was achieved by boiling the beads with 120 
sample buffer (see online methods). CpOGAD298N, but not the double mutant, was successful in pulling down O-121 
GlcNAcylated but not unmodified TAB1, showing that the pull down occurred in an O-GlcNAc specific and 122 
CpOGA active-site dependent manner (Fig. 1b). The affinity of CpOGAD298N for glycosylated TAB1 was therefore 123 
sufficient for it to pull down the modified substrate, suggesting that it might be suitable for the enrichment of O-124 
GlcNAcylated proteins from more complex samples such as cell/tissue lysates.  125 
 126 
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Prior to applying it to enrich for O-GlcNAcylated proteins from cell/tissue lysates, we wished to further dissect 127 
the substrate specificity of CpOGAD298N. It is evident from our previous work that CpOGAD298N is a specific 128 
detector of O-linked GlcNAc in HEK293 cell lysates as well in lysates of Drosophila S2 cells and embryos; 129 
PNGaseF treatment of lysates does not result in any visible alteration of signal obtained using CpOGAD298N as a 130 
probe for detection by Far Western blotting18. To investigate whether CpOGAD298N would bind to N-GlcNAc 131 
moieties in lysates resulting from endogenous ENGase activity, we performed a fluorescence polarization assay 132 
we previously described18, using an N-GlcNAcylated synthetic peptide derived from Cathepsin D. It appears that 133 
the conformation of the sugar/peptide backbone in a short peptide containing an O-linked GlcNAc moiety vs. an 134 
N-linked GlcNAc moiety affects CpOGAD298N binding, as no detectable binding was observed when up to 2.5 mM 135 
of the N-linked GlcNAc containing peptide derived from Cathepsin D (SYLN(GlcNAc)VTR)31 was used 136 
(Supplementary Fig. 2). In contrast, CpOGAD298N binds to an O-GlcNAc peptide derived from dHCF 137 
(VPST(GlcNAc)MSAN) with an affinity of 36 µM (highest concentration of peptide used - 2.7 mM)18. SPR 138 
experiments to determine differences in the binding to GlcNAc vs. GlcNAc(β1-4)GlcNAc reveal that CpOGAD298N 139 
binds the latter with a 20-fold lower affinity (29 µM vs. 590 µM) (Supplementary Fig. 3), suggesting that the 140 
mutant protein would have poor affinity for terminal GlcNAc moieties on extended glycan structures and would 141 
therefore preferentially bind to O-GlcNAc. 142 
 143 
To determine how the substrate trap compares to previously published enrichment methods applied to lysates 144 
of a single cell line32,33, pull downs were also performed from HeLa cell lysates. Lysates were incubated for 90 145 
min at 4 °C with Halo-tagged CpOGAD298N or the control mutant CpOGAD298N,D401A covalently coupled to saturation 146 
to HaloLink beads (schematic in Fig. 2a). To ensure that the eluents contained O-GlcNAcylated proteins captured 147 
specifically by the CpOGAD298N active site, elution was achieved by displacement with a molar excess of the 148 
OGA inhibitor Thiamet G34 (Fig. 2a), which retains binding to the inactive CpOGAD298N mutant (with a Kd of 688 149 
nM, Supplementary Fig. 4). The pull down performed with CpOGAD298N, but not that performed with the 150 
CpOGAD298N,D401A  negative control, resulted in an overall qualitative enrichment of O-GlcNAcylated proteins as 151 
visualized by Western blotting of samples using the RL2 antibody (representative blot in Fig. 2b and 152 
Supplementary Figs. 5-6), suggesting that this approach is a suitable enrichment method for complex samples. 153 
To identify the O-GlcNAcylated proteins enriched, three independent replicate pull downs were performed, 154 
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including negative controls with CpOGAD298N,D401A. Eluates from these pull downs were processed and subjected 155 
to mass spectrometry. A total of 915 protein accessions were identified from the HeLa eluates, of which 859 156 
were significantly enriched (4-fold, p < 0.05) in the CpOGAD298N mutant pull down compared to the control 157 
CpOGAD298N,D401A pull down (Supplementary Dataset 1). Bona fide O-GlcNAcylated substrates, such as the 158 
histones H2A, H2B, H3 and H435,36, c—Rel37, CREB38, CK2α39,40, TAB130 and OGT21,41 were among the proteins 159 
identified, thus validating the enrichment method. In contrast, a previously published study33 identified 199 160 
significantly enriched proteins from HeLa cells using a tagging via substrate (TAS) approach, whereby a cell 161 
permeable azide modified analog of UDP-GlcNAc is used for the metabolic labeling of OGT substrates, which 162 
are then chemoselectively enriched. 49 of the significantly enriched proteins identified by us were also identified 163 
by that study33 (Supplementary Table 1). We identified 550 high confidence O-GlcNAc peptide sequence 164 
matches in 3 replicate MS analyses (3 with ETD site assignments). These resulted in a total of 61 high confidence 165 
O-GlcNAc peptides being identified that mapped to 29 of the 859 identified proteins (Supplementary Dataset 2 166 
and Supplementary Table 2). This represents 3.3% of significantly enriched proteins on which O-GlcNAc sites 167 
were mapped, and is comparable to the 3.8% of significantly enriched proteins (using a metabolic 168 
labeling/chemoselective capture approach coupled to BEMAD) from denatured HEK293 cell lysates on which a 169 
previous study mapped O-GlcNAc sites32. Interestingly, 373 significantly enriched proteins identified by us from 170 
HeLa cells were also identified in that study in HEK293 cells with a large number of substrates unique to both 171 
studies (Supplementary Table 3).  The prime advantage of enrichment using CpOGAD298N lies in the fact that no 172 
derivatization of O-GlcNAc moieties is required prior to enrichment unlike in metabolic (for cell lines) or 173 
chemoenzymatic (for tissue samples) labeling - it is a one-step method. Also, unlike WGA, CpOGAD298N 174 
possesses better affinity for O-GlcNAc, potentially enabling the enrichment and identification of a larger number 175 
of substrates. 176 
 177 
Enrichment of O-GlcNAc proteins from Drosophila embryos 178 
We next used CpOGAD298N to enrich O-GlcNAcylated proteins from Drosophila embryo lysates in an attempt to 179 
begin to identify the O-GlcNAc proteome responsible for the sxc null phenotypes. A total of 3558 proteins 180 
accessions (isoforms of proteins and redundant entries with unique Uniprot accessions contribute to this number) 181 
 9 
were identified (Supplementary Dataset 3), of which 2358 were significantly enriched (4-fold, p < 0.05) in the 182 
CpOGAD298N mutant pull down compared to the control CpOGAD298N,D401A pull down (Supplementary Dataset 3). 183 
 184 
2044 of the 2358 proteins enriched were recognised by PANTHER42, which was used for Gene Ontology (GO) 185 
analysis of the data and 881 cellular component hits were obtained. The majority (678) of the hits are 186 
nucleocytoplasmic (cell part, organelle and macromolecular complexes in the nucleus and cytoplasm), with 84 187 
proteins being classified as membrane proteins, 116 as secreted or extracellular matrix proteins, 2 as synaptic 188 
proteins and 1 as a cell junction protein (Fig. 2c). Significantly enriched (p < 0.05, Bonferroni correction for 189 
multiple testing applied) GO cellular compartment terms are detailed in Supplementary Table 4.  190 
 191 
Protein class analysis (performed using PANTHER) revealed that nucleic acid binding proteins represent the 192 
largest protein class identified, with 14% (289 out of 2136: 2044 recognised proteins with 2136 protein class hits) 193 
of proteins belonging to this class, most of these involved in RNA transport and processing (Fig. 3a). 194 
Transcription factors represent 4% of classified proteins and include Dp, Taf6, Cand1, fkh and T-related protein 195 
(byn orthologue). In mouse synaptic membranes, kinases have been shown to be more frequently O-196 
GlcNAcylated than other protein classes in general (16% versus 10%, p < 3.6 × 10−4)22.  In contrast, kinases and 197 
phosphatases combined comprise only 5% (~ 2.5% each) of classified proteins in our dataset and do not display 198 
a statistically significant overrepresentation (Fig. 3a, Supplementary Table 5). Protein kinases identified include 199 
the Akt-1, Cdk7, Cdc2 and Abl orthologues, while protein phosphatases identified include the PP2A 55 kDa 200 
subunit and Ptp4E, among others. While histones themselves are absent from the dataset, the HDACs Rpd3 201 
and HDAC3 are present. The putative HAT Enok is also present, as is the bromodomain containing homeotic 202 
protein female sterile (fs(1)h- Brd2 orthologue). Significantly enriched (p < 0.05, Bonferroni correction for multiple 203 
testing applied) protein classes along with fold enrichment values are listed in Supplementary Table 5.  204 
 205 
Pathway analysis (performed using PANTHER) identified 33 of 2044 mapped protein accessions (~ 1.6%) as 206 
functioning in the Wnt signaling pathway (Supplementary Fig. 7). Examples of the Wnt signaling proteins 207 
identified are cadherin-87A, the acetyltransferase Neijre (CREB-binding protein/CBP orthologue), the HDAC 208 
Rpd3, the mor orthologue, CK1, and the helicase domino. Other proteins in the dataset are involved in pathways 209 
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such as the ubiquitin proteasome pathway, DNA replication, apoptosis and cytoskeletal regulation by Rho 210 
GTPase (Supplementary Fig. 7). Interestingly, many proteins involved in these pathways are also implicated in 211 
the pathogenesis of Huntington’s and Parkinson’s disease. Mutations in huntingtin for example, affect its 212 
interaction with hits like CBP43.  213 
 214 
Identification of O-GlcNAc proteins linked to development  215 
We next examined the O-GlcNAc sites on enriched proteins. In the CpOGAD298N pull downs we identified, in three 216 
experiments, a total of 268 high confidence O-GlcNAc peptide sequence matches (32 with ETD site 217 
assignments) (Supplementary Dataset 4 and Supplementary Tables 6-7); ETD fragmentation spectra for two 218 
HexNAc peptides are shown in Fig. 3b-c). These resulted in a total of 52 high confidence O-GlcNAc peptides 219 
being identified (Supplementary Dataset 4) that were mapped on a total of 43 proteins (Supplementary Table 7). 220 
In contrast, only 3 HexNAc peptide sequence matches were identified in the CpOGAD298N,D401A pull downs (none 221 
of which with ETD site assignments) (Supplementary Table 6). 222 
 223 
The majority of the high confidence O-GlcNAc sites are on nuclear/nucleocytoplasmic proteins. Tay (AUTS2 – 224 
like protein), Grunge (Gug – atrophin orthologue), myopic (mop – HDPTP orthologue), and lingerer (lig – UBA 225 
domain containing protein) are examples of bona fide O-GlcNAcylated proteins identified in this study and many 226 
of these are conserved across evolution. Our dataset also includes the nuclear pore proteins (Nups) (recently 227 
reviewed44), Ataxin-2 (Atx2)45, CF11970 (NFRKB orthologue)46 and HCF47, which have previously been shown 228 
to be O-GlcNAcylated in other organisms although the role of the modification on these proteins is as yet not 229 
understood. GO analysis using STRING48 to determine the biological processes associated with these O-230 
GlcNAcylated proteins categorizes 19 of the 42 proteins mapped as being involved in anatomical structure 231 
development and morphogenesis, with four (if, Gug, tay and LanA) amongst those specifically associated with 232 
appendage development/morphogenesis, a process clearly affected in OGT null mutant flies given the 233 
phenotypes observed (e.g. the homeotic transformation of antennae to prothoracic legs and wings to haltere-like 234 
structures3). Interestingly, 11 hits are classified as being involved in nervous system development and include 235 
Atx-2 and Iswi.  236 
 237 
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Improper O-GlcNAc modification of Ph, one of the most prominent substrates of OGT in Drosophila has been 238 
proposed to be responsible for the OGT/sxc phenotypes via misexpression of Hox genes7,9. Nevertheless, 239 
numerous transcription factors and cell signalling molecules have been identified in this study as being O-GlcNAc 240 
modified. These data therefore suggest the possibility that some of the phenotypes associated with the lack of 241 
OGT activity may be downstream of hypo-O-GlcNAcylation of one of the non-Ph OGT substrates. Site mapping 242 
confirmation in this study establishes Gug as a genuine OGT substrate. We also identified O-GlcNAcylated 243 
peptides from Gug in immunoprecipitates obtained from embryo lysates using the anti-O-GlcNAc antibody RL2 244 
but not an isotype control antibody, thereby orthogonally confirming its modification status (Supplementary Fig. 245 
8a shows the EThcD fragmentation spectrum for one of the HexNAc peptides identified). Gug is a nuclear 246 
receptor corepressor, which was identified in a screen designed to identify regulators of one of the other O-247 
GlcNAc proteins in the embryo O-GlcNAc proteome, teashirt49. Since then the functions of Gug in transcriptional 248 
regulation of EGF receptor signalling50, as a co-repressor for Even skipped51, Tailless52 and Cubitus interruptus53 249 
have been established, outlining its multiple roles during embryonic development. One of the other identified O-250 
GlcNAc modified substrates is mop (also orthogonally verified as being modified using an anti-O-GlcNAc 251 
antibody, EThcD fragmentation spectrum in Supplementary Fig. 8b). A protein associated with intracellular 252 
vesicles, mop, was found to be essential for transit of ubiquitylated EGF receptor to lysosomes54. In addition, 253 
mop is also involved in distribution of integrins during oogenesis55, endocytosis and activation of the Toll56, 254 
Wnt/Wingless57, Frizzled58 and Yorkie59 pathways also affecting respective downstream signalling. 255 
To investigate how reduced O-GlcNAc modification of two of these OGT substrates, Gug and mop, affects their 256 
function, genetic interaction experiments were performed. We used an OGT catalytic hypomorphic allele, 257 
OGT/sxcH537A (henceforth represented as sxcH537A), that we have generated using CRISPR gene editing 258 
(Mariappa et al., Under revision, J. Biol. Chem.). This ensured that any potential genetic interaction we observed 259 
was a consequence of reduced OGT catalytic activity and therefore decreased O-GlcNAc modification of Gug 260 
and mop. Recessive lethal alleles Gug03928 (P element insertion)50 and mopT482 (Q1968Stop)54 were crossed into 261 
either homozygous or heterozygous sxcH537A background. CRISPR control (Cr Control) flies were generated from 262 
the BL51323 stock used for CRISPR injections and subjected to the same crossing scheme as the sxcH537A 263 
mutant lines. None of the Cr Control (Fig. 4a, Supplementary Fig. 9), OGT/sxcH537A homozygotes (Fig. 4b, 264 
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Supplementary Fig. 9) or heterozygotes for Gug03928 and mopT482 (Supplementary Fig. 9) displayed wing vein 265 
deposition defects. About 2% and 1% of sxcH537A/+;Gug03928/+ and sxcH537A /+;mopT482/+ double heterozygotes 266 
had a short L5 longitudinal wing vein that did not reach the wing margin (Supplementary Fig. 9, Supplementary 267 
Table 8). This phenotype was enhanced on further reduction in OGT activity in flies homozygous for the sxcH537A 268 
allele and heterozygous for either Gug03928 and mopT482; to 14% in sxcH537A;Gug03928/+ flies and 8% 269 
sxcH537A;mopT482/+ flies (Fig. 4c-d and Supplementary Table 8). More of the sxcH537A/sxcH537A;Gug03928/+ flies (5%) 270 
had the short L5 wing vein defect in both the wings as compared to the sxcH537A/sxcH537A;mopT482/+ flies (0.6%, 271 
Supplementary Table 8). These data establish a genetic interaction between the hypomorphic OGT/sxc allele 272 
and alleles of two of the OGT substrates Gug and mop. Given that both Gug50 and mop54 have roles in EGF 273 
signalling-dependent wing vein specification, O-GlcNAc modification of these two proteins could potentiate their 274 
function in EGF signalling.   275 
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Discussion 276 
 277 
Unlike OGT knockout mice, which do not survive beyond the single cell stage60, OGT null flies develop to the 278 
pharate adult stage and display the hallmark phenotypes of mutants of polycomb group (PcG) proteins3. This, in 279 
addition to the relatively rapid generation time and amenability to genetic manipulation, renders Drosophila 280 
melanogaster an attractive model organism in which to dissect the role of O-GlcNAc on proteins, particularly in 281 
the context of early development. Targeted investigation of all known members of the PcG has led to the 282 
identification of polyhomeotic (ph) as a key OGT substrate from this class of proteins7. The O-GlcNAcylation of 283 
ph has been suggested to be important in preventing its self-aggregation9. The discovery that the phenotypes of 284 
OGT null mutants resemble a less severe version of the phenotypes of the ph null mutant has led to the 285 
suggestion that the loss of O-GlcNAc on ph is the key driver of the manifestation of the defects exhibited by OGT 286 
null flies10. Ph is not, however, the sole OGT substrate in Drosophila, and the role of O-GlcNAc on a handful of 287 
other proteins has been studied in the fly11-14,16,17. Nevertheless, it is not understood how the O-GlcNAc proteome 288 
maps to processes that are critical for development in both Drosophila and vertebrates.  289 
 290 
We previously described CpOGAD298N as a versatile and specific tool for the detection of O-GlcNAc in mammalian 291 
and Drosophila cell lysates, and used it to demonstrate that protein O-GlcNAcylation is dynamic during 292 
Drosophila embryogenesis18. We have now successfully deployed CpOGAD298N for the enrichment of O-293 
GlcNAcylated proteins from Drosophila embryos and have discovered novel substrates of OGT in the fly. 294 
Interestingly, genetic interactions of a hypomorphic OGT/sxc allele with lethal recessive alleles of two of the bona 295 
fide substrates, Gug and mop, lead to a similar phenotype wherein the L5 wing vein is short. Reduced deposition 296 
of wing vein material is observed in mop mutant wings, possibly affecting EGF signalling54. Conversely, EGF 297 
signalling dependent wing vein deposition is enhanced in a Gug mutant background50. It is possible that O-298 
GlcNAc modification of Gug and mop could affect their role in EGF signalling via mechanisms that will need to 299 
be further investigated. Nevertheless, given the role of both these proteins in numerous other cell signalling and 300 
transcriptional control events, O-GlcNAcylation of Gug or mop could be modulating one/multiple such 301 
downstream events. In addition, we have also observed genetic interaction between sxcH537A with a Hcf null allele 302 
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with respect to specification of the thoracic scutellar bristles (Mariappa et al., Under revision, J. Biol. Chem.), 303 
thus underlining the multiple roles that can be ascribed to O-GlcNAcylated substrates.  304 
 305 
The identification and validation of proteins like Gug and mop as bona fide OGT substrates, and the 306 
determination of O-GlcNAc sites on them, paves the way for future studies aimed at investigating the effect of 307 
O-GlcNAc on these proteins and the processes they regulate. While some of these hits could contribute to the 308 
homeotic transformations observed in OGT/sxc null flies, others might reveal novel, potentially conserved 309 
functions of O-GlcNAc through the identification of subtler phenotypes in non-lethal OGT/sxc mutants. 310 
  311 
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Figure legends 463 
 464 
Figure 1: A point mutant of CpOGA can be exploited as a substrate trap for the enrichment of O-465 
GlcNAcylated proteins.  466 
(a) The inactive mutant CpOGAD298N can bind to substrate proteins (substrate is shown as a yellow cartoon, 467 
with GlcNAc depicted with pink sticks) but cannot hydrolyse GlcNAc therefore trapping O-GlcNAc 468 
modified proteins. The double mutant CpOGAD298N,D401A cannot bind O-GlcNAcylated proteins and 469 
therefore cannot act as a substrate trap  470 
(b) Unmodified or O-GlcNAcylated TAB1 was incubated with Halo-CpOGAD298N coupled covalently to 471 
HaloLink beads. Pull down using the binding-deficient mutant CpOGAD298N,D401A was included to test the 472 
specificity of the pull down. Input, flow-through and elution fractions were blotted and probed with the 473 
antibodies mentioned. Elutions were performed by boiling the beads with sample buffer. TAB1 was pulled 474 
down in an O-GlcNAc specific manner by CpOGAD298N but not the control probe as evidenced by the 475 
presence of modified but not unmodified TAB1 in the elution fractions from CpOGAD298N.  476 
 477 
Figure 2: Pull down of O-GlcNAcylated proteins by CpOGAD298N.  478 
(a) Schematic of the CpOGAD298N enrichment method. Halo-tagged CpOGA mutants covalently coupled to 479 
HaloLink beads were used to pull down O-GlcNAcylated proteins. Elution of proteins from the beads was 480 
achieved by using a molar excess of the OGA inhibitor Thiamet G. Eluted proteins were concentrated 481 
using a spin concentrator and processed for mass spectrometry. 482 
(b) Pull down from Drosophila embryo lysates using CpOGAD298N, but not the control mutant, results in the 483 
enrichment of O-GlcNAcylated proteins detected in the elution fractions.  484 
(c) Cellular localization of proteins identified by CpOGAD298N. Cellular component analysis of all proteins 485 
identified by CpOGAD298N. 486 
 487 
Figure 3: Protein class grouping of proteins identified by CpOGAD298N and example ETD fragmentation 488 
spectra for HexNAc modified peptides from Host Cell Factor (HCF) and Nucleoporin 153 (Nup153) 489 
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(a) Protein classes represented by identified proteins. Uniprot accessions of significantly enriched proteins 490 
(in CpOGAD298N pulldown vs. control pulldown) provided in Supplementary Dataset 3 were used as 491 
input for analysis on PANTHER database. 492 
(b) and (c) Example ETD fragmentation spectra for HexNAc modified peptides from Host Cell Factor (HCF) 493 
(b) and Nucleoporin 153 (Nup153) (c). One peptide each from Host Cell Factor and Nucleoporin 153kD 494 
are shown. Peptide fragments were assigned using Mascot and Proteome Discoverer 2.0. Signals of 495 
charged reduced species of the precursor and neutral losses associated with it in the spectrum were 496 
filtered out. For clarity, only c[+1], red, and z[+1], blue, ions are annotated.. The sequence relevant to 497 
each ion is shown, lower case “s”/“t” indicate the HexNAc modified residues. 498 
 499 
Figure 4: OGT catalytic activity potentiates the function of its substrates Grunge and myopic.  500 
Genetic interaction between OGT/sxcH537A and Gug03928 or mopT482 alleles was assessed in the adult wing. In the 501 
Cr control (a), OGT/sxcH537A (b) homozygotes or Gug03928 or mopT482 heterozygotes have a complete L5 502 
longitudinal wing vein that reaches the wing margin. In OGT/sxcH537A/OGT/sxcH537A;Gug03928/+ (c) or 503 
OGT/sxcH537A/OGT/sxcH537A;mopT482/+ (d) flies, 14% and 8% of the flies, respectively, have a shorter L5 wing 504 
vein. Fewer of the double homozygotes, OGT/sxcH537A/+;Gug03928/+ or OGT/sxcH537A/+;mopT482/+ display this 505 
phenotype as demonstrated by the quantification in (e). Arrows in (c) and (d) point to the short L5 wing vein 506 
phenotype. 507 
508 
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Online methods 509 
 510 
Drosophila embryos 511 
Embryos from w1118 wild type flies were used. Fly stocks were maintained by flipping vials once every ten days. 512 
Embryos (0-16 h) were collected on apple juice agar plates at 25 °C overnight. For embryo collections, flies were 513 
assigned from vials in a rack in random order to three separate cages to represent three biological replicates. 514 
Collected embryos were dechorionated with bleach and snap frozen in dry ice and stored at -80 ºC until they 515 
were processed. Samples were collected over time and on independent occasions in this manner till enough 516 
material was obtained for further processing. Lysates were prepared as described below. Bradford assay or 517 
Pierce 660 nm protein assay was used to quantify cell lysates.  518 
 519 
Cell culture 520 
HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% fetal 521 
bovine serum (FBS), L-glutamine, and penicillin streptomycin at 37 °C with humidified air at 5% CO2. Cells were 522 
plated on 10 cm dishes and grown to 80% confluence prior to harvesting. 523 
 524 
Protein expression and purification 525 
Plasmids containing N-terminally Halo-tagged CpOGA (31-618) were transformed into E. coli BL21-Gold (DE3) 526 
pLysS cells (Agilent). Cells were grown overnight at 37 °C in Luria-Bertani medium containing 50 μg/ml 527 
Kanamycin (LB-Kan) and used at 10 mL/L to inoculate of fresh LB-Kan. Cells were grown to an OD600 of 0.6-0.8, 528 
transferred to 18 °C and induced with 250 µM IPTG and harvested after 16 h by centrifugation for 30 min at 3500 529 
rpm (4 °C). Cell pellets were resuspended in 10-20 mL of 50 mM Tris, 250 mM NaCl at pH 7.5 (lysis buffer) 530 
supplemented with protease inhibitors (1 mM benzamidine, 0.2 mM PMSF and 5 µM leupeptin), DNAse and 531 
lysozyme prior to lysis. Cells were lysed using a continuous flow cell disrupter (Avestin, 3 passes at 20 kpsi) and 532 
the lysate was cleared by centrifugation (30 min, 15,000 rpm, 4 °C). Supernatants were collected and loaded 533 
onto a HisTrap HP column (GE Healthcare Life Sciences) charged with NiSO4 and pre-equilibrated with lysis 534 
buffer. The column was washed with 10 column volumes of lysis buffer. Proteins were eluted with a linear 535 
gradient of imidazole (0-500 mM) over 20 column volumes. Late elution fractions were pooled and dialysed into 536 
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1 x TBS and snap frozen with a final concentration of 20% glycerol and stored at -80 °C until use. Untagged 537 
proteins used for fluorescence polarization and surface plasmon resonance experiments were prepared as 538 
described previously18.  539 
 540 
Fluorescence Polarimetry 541 
Experiments were performed as described before18. Briefly, to avoid receptor depletion, reaction mixtures for 542 
competition binding experiments contained 5 nM fluorescent probe, 7 nM of CpOGAWT (receptor)/20 nM 543 
CpOGAD298N (receptor) and a range of concentrations of ligands. Reactions were allowed to stand at room 544 
temperature for 10 min. Highest amount of fluorescent probe bound to CpOGAD298N in the absence of competing 545 
ligands was arbitrarily set as 100%. EC50 values were determined by fitting non-linear regression curves with 546 
Prism (GraphPad) and converted to Kd as described before18. All experiments were performed in triplicate. 547 
 548 
Surface Plasmon Resonance 549 
Experiments were performed as described before18. Briefly, biotinylated proteins were captured on a neutravidin 550 
surface prepared on high capacity amine sensor chip of a Mass-1 instrument (Sierra Sensors) at densities 551 
3,600–3,900 RU. Ligands were injected over captured proteins at a flow rate of 30 µL min–1 in running buffer (25 552 
mM Tris pH 7.5, 150 mM NaCl, 0.05% Tween20), with each compound injected in duplicates in concentration 553 
series adjusted specifically around their affinities. Association was measured for 60 s and dissociation for 120 s. 554 
All data were double referenced for blank injections of buffer and biotin-blocked Streptavidin surface. Data 555 
processing and analysis were performed using Analyser 2 (Sierra Sensors) and Scrubber 2 (BioLogic Software). 556 
 557 
CpOGAD298N pull downs  558 
Halo-tagged CpOGA proteins were purified as described above and coupled to MagneTMHaloTag® Beads 559 
(Promega) as per the manufacturer’s instructions. Briefly, MagneTMHaloTag® Beads (Promega) were 560 
equilibrated with 50 mM Tris pH 7.5, 150 mM NaCl (wash buffer) supplemented with 0.05% Tween-20 (binding 561 
buffer). The binding capacity of the beads for tagged CpOGA was determined to be 8 mg per mL of settled 562 
beads. Beads were coupled to saturation with CpOGA for 90 min h at 4 °C then washed extensively with wash 563 
buffer and stored on ice. Halo-CpOGA beads were prepared freshly for each experiment.  564 
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 565 
For the TAB1 pull down experiment, in vitro O-GlcNAcylation of TAB1 was performed by incubating 24 µg (18.2 566 
µM) of TAB1 with 10 µg (4.1 µM) hOGT and 10 mM UDP-GlcNAc in a final volume of 30 µL for 3 h at 37 °C. The 567 
reaction was stopped by the addition of a final concentration of 20 mM of UDP. ‘Unmodified TAB1’ was the 568 
product of reactions containing all components except for UDP-GlcNAc. The reactions were split in four equal 569 
volumes (containing 3 µg of total TAB1 each), of which two were retained for loading as input and one each of 570 
the remainder of the two loaded onto 50 µL of a 20% slurry of HaloLink beads coupled to saturation with 571 
CpOGAD298N or CpOGAD298N,D401A . The incubation with beads was performed in a total volume of 200 µL made 572 
up with binding buffer for 1 h at 4 °C. The flow-through was collected, beads washed 3 times with wash buffer 573 
and bound protein eluted using 200 µL of 10 mM Tris pH 6.8, 4% SDS, 200 mM DTT by boiling for 2 min. The 574 
‘input’ fractions were also made up to a volume of 200 µL and 8 µL of all fractions were subjected to SDS PAGE 575 
and Western blotting. The antibodies used were Anti-TAB1 (C25E9 – Cell Signaling, 1:5000) and anti-O-GlcNAc 576 
RL2 (ab2739 – Abcam, 1:3000 or 1:1000) 577 
 578 
Drosophila embryo lysates and HeLa lysates were prepared with RIPA buffer (50 mM Tris pH 7.5, 1% NP-40, 579 
0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA and 50 mM NaF). For each replicate 580 
experiment, protein lysates were split in half to carry out pull downs with either CpOGAD298N or the control 581 
CpOGAD298N,D401A. 7 mg of lysates were incubated with 200 µL of settled HaloLink beads coupled to saturation 582 
with CpOGAD298N or CpOGAD298N, D401A for 90 min at 4 °C. The flow through was collected and the beads washed 583 
extensively with wash buffer. Bound proteins were eluted by incubating the beads 2 x for 30 min at 4 °C with 250 584 
µL wash buffer supplemented with 3 mM Thiamet G. The eluents were concentrated using a 10 kDa molecular 585 
weight cut off spin concentrator and ~2 µg set aside for Western blotting and the rest prepared for mass 586 
spectrometry analysis as below. Experiments were performed in triplicate.  587 
 588 
RL2 immunoprecipitation 589 
5 mg of embryo lysates prepared as described above were incubated for 3 h at 4 °C with 5 μg of RL2 or Mouse 590 
normal IgG1 (Cell Signaling) antibody bound to Protein G dynabeads (Invitrogen) as per the manufacturer’s 591 
instructions. The flow through was collected and incubated with freshly coupled RL2/IgG1 (5 μg) dynabeads 592 
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overnight at 4 °C. The immunoprecipitates were washed several times with 500 μL of 1 X TBS containing 0.02% 593 
Tween 20 per wash and eluted by boiling the beads for 5 min in 50 mM Tris pH 6.8 containing 4% SDS and 200 594 
mM DTT. Eluates were processed for mass spectrometry as described below.  595 
 596 
Sample preparation for mass spectrometry 597 
Samples were run halfway down precast NuPAGE 4-12% Bis-Tris gels (Invitrogen) and stained in clean plastic 598 
containers with InstantBlue (Expedeon) Coomassie stain then de-stained using mass spec grade water (VWR). 599 
Each lane on the gel was excised into up to 0.5 cm X 0.5 cm sections and then further diced into 1 mm cubes 600 
using a clean scalpel. The excised gel pieces were de-stained till colourless using 50% methanol, rinsed with 601 
50% acetonitrile and subsequently with 50% acetonitrile in 50 mM ammonium bicarbonate buffer (wash buffer). 602 
In-gel reduction was performed by incubating gel pieces in 10 mM DTT made in 50 mM ammonium bicarbonate 603 
for 20 min at RT, then alkylated by adding 50 mM iodoacetamide made in 50 mM ammonium bicarbonate buffer 604 
for 30 min at RT in the dark. The gel pieces were then washed several times with wash buffer and dehydrated 605 
by incubating for 10 min at RT in 100% acetonitrile. Gel pieces were then swelled with enough 25 mM 606 
triethylammonium bicarbonate buffer to cover them and subjected to enzymatic digestion using Trypsin (mass 607 
spec grade, Promega) at 5 µg per mL of triethylammonium bicarbonate buffer at 30 °C for 16 h. The solution 608 
containing liberated peptides was then collected and more peptides extracted from the gel pieces using 50% 609 
acetonitrile containing 2.5% formic acid. Peptides were pooled and dried in a SpeedVac and stored at -80 °C 610 
until MS analysis.  611 
 612 
Mass spectrometry and data analysis 613 
HCD and ETD mass spectrometry analysis (or EThcD for RL2 immunoprecipitates) was performed by LC-MS-614 
MS on a Fusion ion trap-orbitrap hybrid mass spectrometer (Thermo Scientific) coupled to a U3000 RSLC HPLC 615 
(Thermo Scientific). 50%/10% of the Drosophila embryo samples/HeLa samples were injected. Peptides were 616 
trapped on a nanoViper Trap column, 2 cm x 100 µm C18 5 µm 100 Å (Thermo-Fisher, 164564) then separated 617 
on a 50 cm EasySpray column (Thermo, ES803) equilibrated with a flow of 300 nl/min of 3% Solvent B [Solvent 618 
A was 2% acetonitrile, 0.1% formic acid, 3% DMSO in H2O; Solvent B was 80% acetonitrile, 0.08% formic acid, 619 
3% DMSO in H2O]. The elution gradient was as follows, Time (min): Solvent B (%); 0:3, 5:3, 55:25, 74:40, 74.5: 620 
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99, 79.5:99, 80:3, 90:3. Data were acquired in the data-dependent mode, automatically switching between MS 621 
and MS-MS acquisition. MS full scan spectra were acquired in the orbitrap with S-lens RF level of 60 %, 622 
resolution of 120000 (scan range m/z 400-1600), with a maximum ion injection time of 50 ms, and AGC setting 623 
of 400000 ions. HCD normalized collision energy was set to 30% and fragment ions were detected in the linear 624 
ion trap using 1 microscan, with a maximum injection time of 250 ms and AGC setting of 100 ions. ETD MS2 625 
analyses were triggered by the presence of product ions with m/z 204.0867 (HexNAc oxonium) and/or 138.0545 626 
(HexNAc fragment) and detected in the Ion Trap, AGC Target 10000 and maximum injection time of 105 ms. 627 
EThcD reactions were triggered as for ETD  or by the presence of the 366.1396  HexNAcHex ion, and detected 628 
in the orbitrap (resolution of 30000, scan range m/z 120-2000) using 1 microscan, AGC setting of 300000 ions 629 
and maximum injection time of 150 ms. Data files were analysed for HexNAc peptides by Proteome Discoverer 630 
2.0 (Thermo), using Mascot 2.4.1 (Matrix Science), and searched against the Uniprot_DROME database or the 631 
Uniprot_HUMAN database as appropriate. Allowance was made for fixed, (carbamidomethyl (C)), and variable 632 
modifications (oxidation (M), dioxidation (M), phospho (S/T) and HexNAc (S/T)). Protein abundance analysis 633 
was performed using MaxQuant 1.5.1.7 and data was further analysed using the Perseus software package; 634 
significant proteins were identified using a two-tailed t-test (p < 0.05). 635 
 636 
Drosophila genetics 637 
The following fly stocks were obtained from Bloomington Drosophila Stock Centre: Gug03928/TM3, Sb1, Ser1 and 638 
mopT482/TM6B, Tb1. The catalytically hypomorphic OGT/sxcH537A flies were generated using CRISPR/Cas9 639 
gene editing (Mariappa et al., Under revision, J. Biol. Chem.). The BL51323 Vasa::Cas9 stock used for the 640 
CRISPR injections were crossed with the balancer stocks to eliminate the Vasa::Cas9 containing X chromosome 641 
similar to the mutant flies to derive the CRISPR control (Cr control) stock. To derive double heterozygotes Cr 642 
control virgins were crossed with OGT/sxcH537A/OGT/sxcH537A;Gug03928/TM6 or 643 
OGT/sxcH537A/OGT/sxcH537A;mopT482/TM6 flies. To derive Gug03928 or mopT482 Cr control virgins were crossed with 644 
Gug03928/TM3, Sb1, Ser1 or mopT482/TM6B, Tb1 flies, respectively. Wing phenotypes of flies of the various 645 
genotypes were assessed using a Motic SMZ microscope. Wing preparations were made by dissecting whole 646 
wings from the flies and transferring them into isopropanol for 24 h. The wings were then mounted in DPX 647 
Mounting medium (Sigma) and imaged with a Leica E24 HD dissection microscope.  648 
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